UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): February 27, 2020

TransMedics Group, Inc.

(Exact Name of Registrant as Specified in Charter)

Massachusetts (State or Other Jurisdiction of Incorporation) 001-38891 (Commission File Number) 83-2181531 (I.R.S. Employer Identification No.)

200 Minuteman Road Andover, Massachusetts 01810 (Address of Principal Executive Offices, and Zip Code)

(978) 552-0900 Registrant's Telephone Number, Including Area Code

| Title of each class Common Stock, no par value per share | Trading Symbol(s) TMDX | Name of each exchange on which registered The Nasdag Stock Market LLC |
|--|--|---|
| | | |
| urities registered pursuant to Section 12(b) of the Act: | | |
| | | |
| Pre-commencement communication pursuant to Rule 1 | 3e-4(c) under the Exchange Act (17 | CFR 240.13e-4(c)) |
| Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | | |
| Written communication pursuant to Rule 425 under the | Securities Act (17 CFR 230.425) | |
| ck the appropriate box below if the Form 8-K filing is intowing provisions (<i>see</i> General Instruction A.2. below): | tended to simultaneously satisfy the fi | iling obligation of the registrant under any of the |
| | wing provisions (<i>see</i> General Instruction A.2. below): Written communication pursuant to Rule 425 under the Soliciting material pursuant to Rule 14a-12 under the E Pre-commencement communication pursuant to Rule 1 | Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company $\ oxtimes$

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. \Box

Item 1.01 Entry into a Material Definitive Agreement.

On February 27, 2020, TransMedics Group, Inc. (the "Company") entered into an Amendment, by and among by and among TransMedics, Inc., a Delaware corporation (the "Borrower"), the Company, and TransMedics, B.V., a Dutch private limited liability company, and Orbimed Royalty Opportunities II, LP, a Delaware limited partnership (the "Lender") attached to this Current Report on form 8-K as Exhibit 10.1 (the "Amendment"), which amends the Credit Agreement, dated as of June 22, 2018, by and between the Borrower and the Lender.

The Amendment provides that, with respect to the Borrower, "Fiscal Quarter" means a fiscal quarter of any Fiscal Year ending each of March 31, June 30, September 30 and December 31 and "Fiscal Year" means the fiscal year of the Borrower ending December 31 of each calendar year.

The foregoing summary does not purport to be complete and is qualified in its entirety by reference to the Amendment, which is attached as Exhibit 10.1 hereto and incorporated by reference herein in its entirety.

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

On February 27, 2020, the Board of Directors approved a change in the Company's fiscal year end from the last Saturday in December 31. Following such change, the Company's current fiscal year will end on December 31, 2020.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit
No. Description

10.1 Amendment to Credit Agreement, dated as of February 27, 2020, by and among by and among TransMedics, Inc., TransMedics Group, Inc.,

TransMedics, B.V., and Orbimed Royalty Opportunities II, LP

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: February 28, 2020

TRANSMEDICS GROUP, INC.

By: /s/ Stephen Gordon

Name: Stephen Gordon

Title: Chief Financial Officer, Treasurer and Secretary

FIRST AMENDMENT TO CREDIT AGREEMENT

This FIRST **AMENDMENT TO CREDIT AGREEMENT** (this "<u>Amendment</u>") is made and entered into as of February 27, 2020 by and among **TRANSMEDICS, INC.**, a Delaware corporation (the "<u>Borrower</u>"), **TRANSMEDICS GROUP, INC.**, a Massachusetts corporation ("<u>TransMedics Group</u>"), and **TRANSMEDICS B.V.**, a Dutch private limited liability company (*besloten vennootschap met beperkte aansprakelijkheid*) ("<u>TransMedics B.V.</u>" and together with TransMedics Group, the "<u>Guarantors</u>" and each, a "<u>Guarantor</u>"), and **ORBIMED ROYALTY OPPORTUNITIES II, LP**, a Delaware limited partnership (the "<u>Lender</u>").

WHEREAS, the Borrower and the Lender are party to that certain Credit Agreement, dated as of June 22, 2018, by and between the Borrower, as borrower, and the Lender, as lender (as heretofore amended, restated, amended and restated, supplemented or otherwise modified, the "<u>Credit Agreement</u>");

WHEREAS, the Borrower wishes to amend certain provisions of the Credit Agreement as provided in this Amendment;

WHEREAS, Section 8.14(vi) of the Credit Agreement prohibits changing the Fiscal Year or Fiscal Quarter of the Borrower and pursuant to Section 10.1 of the Credit Agreement, the Credit Agreement may be amended in writing and consented to by the Lender and the Borrower.

NOW, THEREFORE, in consideration of the mutual agreements herein contained, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:

- 1. **Definitions**. Capitalized terms used herein without definition shall have the meanings assigned to such terms in the Credit Agreement.
- 2. **Waiver**. The Lender hereby waives any non-compliance by the Borrower, as a result of the change of the Borrower's Fiscal Year and Fiscal Quarters pursuant to this Amendment, with the covenant set forth in Section 8.14(vi) of the Credit Agreement.
- 3. <u>Amendments to Section 1.1 of the Credit Agreement</u>. Upon the satisfaction of the conditions precedent set forth in Section 4 below, the Lender and the Borrower hereby agree that the definitions of "Fiscal Quarter" and "Fiscal Year" in the Credit Agreement shall be amended and restated, respectively, as follows:

"Fiscal Quarter" means a fiscal quarter of any Fiscal Year ending each of March 31, June 30, September 30 and December 31.

"Fiscal Year" means the fiscal year of the Borrower ending December 31 of each calendar year.

4. <u>Conditions to Effectiveness of Amendment</u>. This Amendment shall become effective upon receipt by the Lender of counterpart signatures to this Amendment duly executed and delivered by the Lender, the Borrower and each Guarantor.

- 5. No Implied Amendment or Waiver. Except as expressly set forth in this Amendment, this Amendment shall not, by implication or otherwise, limit, impair, constitute a waiver of or otherwise affect any rights or remedies of the Lender under the Credit Agreement or the other Loan Documents, or alter, modify, amend or in any way affect any of the terms, obligations or covenants contained in the Credit Agreement or the other Loan Documents, all of which shall continue in full force and effect. Nothing in this Amendment shall be construed to imply any willingness on the part of the Lender to agree to or grant any similar or future consent, waiver or amendment of any of the terms and conditions of the Credit Agreement or the other Loan Documents.
- 6. <u>Waiver and Release</u>. TO INDUCE THE LENDER, TO AGREE TO THE TERMS OF THIS WAIVER, THE BORROWER AND THE GUARANTORS (FOR THEMSELVES AND THEIR AFFILIATES) (COLLECTIVELY, THE "<u>RELEASING PARTIES</u>") REPRESENT AND WARRANT THAT AS OF THE DATE HEREOF THERE ARE NO CLAIMS OR OFFSETS AGAINST OR RIGHTS OF RECOUPMENT WITH RESPECT TO OR DEFENSES OR COUNTERCLAIMS TO THEIR OBLIGATIONS UNDER THE LOAN DOCUMENTS AND IN ACCORDANCE THEREWITH THEY:
- (a) WAIVE ANY AND ALL SUCH CLAIMS, OFFSETS, RIGHTS OF RECOUPMENT, DEFENSES OR COUNTERCLAIMS, WHETHER KNOWN OR UNKNOWN, ARISING PRIOR TO THE DATE HEREOF;
- (b) FOREVER RELEASE, RELIEVE AND DISCHARGE THE LENDER, ITS OFFICERS, DIRECTORS, SHAREHOLDERS, MEMBERS, PARTNERS, PREDECESSORS, SUCCESSORS, ASSIGNS, ATTORNEYS, ACCOUNTANTS, AGENTS, EMPLOYEES AND REPRESENTATIVES (COLLECTIVELY, THE "RELEASED PARTIES"), AND EACH OF THEM, FROM ANY AND ALL CLAIMS, LIABILITIES, DEMANDS, CAUSES OF ACTION, DEBTS, OBLIGATIONS, PROMISES, ACTS, AGREEMENTS AND DAMAGES, OF WHATEVER KIND OR NATURE, WHETHER KNOWN OR UNKNOWN, SUSPECTED OR UNSUSPECTED, CONTINGENT OR FIXED, LIQUIDATED OR UNLIQUIDATED, MATURED OR UNMATURED, WHETHER AT LAW OR IN EQUITY, WHICH THE RELEASING PARTIES EVER HAD, NOW HAVE, OR MAY, SHALL, OR CAN HEREAFTER HAVE, DIRECTLY OR INDIRECTLY ARISING OUT OF OR IN ANY WAY BASED UPON, CONNECTED WITH, OR RELATED TO MATTERS, THINGS, ACTS, CONDUCT AND/OR OMISSIONS AT ANY TIME FROM THE BEGINNING OF THE WORLD THROUGH AND INCLUDING THE DATE HEREOF, INCLUDING WITHOUT LIMITATION ANY AND ALL CLAIMS AGAINST THE RELEASED PARTIES ARISING UNDER OR RELATED TO THE LOAN DOCUMENTS OR THE TRANSACTIONS CONTEMPLATED THEREBY. NOTWITHSTANDING ANYTHING TO THE CONTRARY HEREIN, THE RELEASING PARTIES AND THE RELEASED PARTIES HEREBY AGREE THAT THE RELEASE CONTAINED HEREIN DOES NOT INCLUDE A RELEASE OF ANY CLAIM OR OBLIGATION AGAINST THE RELEASED PARTIES ARISING AFTER THE DATE HEREOF UNDER THE TERMS OF THE LOAN DOCUMENTS WHICH CLAIM OR OBLIGATION DOES NOT ARISE, DIRECTLY OR INDIRECTLY, OUT OF AND IS IN NO WAY BASED UPON MATTERS, THINGS, ACTS, CONDUCT AND/OR OMISSIONS OCCURRING PRIOR TO THE DATE HEREOF;

- (c) IN CONNECTION WITH THE RELEASE CONTAINED HEREIN, ACKNOWLEDGE THAT THEY ARE AWARE THAT THEY MAY HEREAFTER DISCOVER CLAIMS PRESENTLY UNKNOWN OR UNSUSPECTED, OR FACTS IN ADDITION TO OR DIFFERENT FROM THOSE WHICH THEY KNOW OR BELIEVE TO BE TRUE, WITH RESPECT TO THE MATTERS RELEASED HEREIN. NEVERTHELESS, IT IS THE INTENTION OF THE RELEASING PARTIES, THROUGH THIS AMENDMENT AND WITH ADVICE OF COUNSEL, FULLY, FINALLY AND FOREVER TO RELEASE ALL SUCH MATTERS, AND ALL CLAIMS RELATED THERETO, WHICH DO NOW EXIST, OR HERETOFORE HAVE EXISTED. IN FURTHERANCE OF SUCH INTENTION, THE RELEASES HEREIN GIVEN SHALL BE AND REMAIN IN EFFECT AS A FULL AND COMPLETE RELEASE OR WITHDRAWAL OF SUCH MATTERS NOTWITHSTANDING THE DISCOVERY OR EXISTENCE OF ANY SUCH ADDITIONAL OR DIFFERENT CLAIMS OR FACTS RELATED THERETO;
- (d) COVENANT AND AGREE NOT TO BRING ANY CLAIM, ACTION, SUIT OR PROCEEDING AGAINST THE RELEASED PARTIES, DIRECTLY OR INDIRECTLY, REGARDING OR RELATED IN ANY MANNER TO THE MATTERS RELEASED HEREBY, AND FURTHER COVENANT AND AGREE THAT THIS AGREEMENT IS A BAR TO ANY SUCH CLAIM, ACTION, SUIT OR PROCEEDING; AND
- (e) REPRESENT AND WARRANT TO THE RELEASED PARTIES THAT THEY HAVE NOT HERETOFORE ASSIGNED OR TRANSFERRED, OR PURPORTED TO ASSIGN OR TRANSFER, TO ANY PERSON OR ENTITY ANY CLAIMS OR OTHER MATTERS HEREIN RELEASED.
- 7. <u>Counterparts</u>. This Amendment may be executed by the parties hereto in several counterparts, each of which shall be an original and all of which shall constitute together but one and the same agreement. Delivery of an executed counterpart of a signature page to this Amendment by e-mail (e.g., "pdf" or "tiff") or telecopy shall be effective as delivery of a manually executed counterpart of this Amendment.
- 8. <u>Governing Law</u>. THIS AMENDMENT SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE INTERNAL LAWS OF THE STATE OF NEW YORK (INCLUDING FOR SUCH PURPOSE SECTIONS 5-1401 AND 5-1402 OF THE GENERAL OBLIGATIONS LAW OF THE STATE OF NEW YORK).

[Signature Page Follows]

IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be executed by their respective officers thereunto duly authorized as of the day and year first above written.

TRANSMEDICS, INC.,

as the Borrower

By: /s/ Stephen Gordon

Name: Stephen Gordon Title: Chief Financial Officer

TRANSMEDICS B.V.,

as Guarantor

By: /s/ Stephen Gordon

Name: Stephen Gordon

Title: Authorized Representative

TRANSMEDICS GROUP, INC.,

as Guarantor

By: /s/ Stephen Gordon

Name: Stephen Gordon

Title: Chief Financial Officer, Treasurer and Secretary

ORBIMED ROYALTY OPPORTUNITIES II, LP,

as the Lender

By OrbiMed Advisors LLC, its investment manager

By: /s/ Sven H. Borko

Name: Sven H. Borko Title: Member

Signature Page to First Amendment to Credit Agreement